Work

24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

Year: 2015

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(16)31944-x

Authors: G.V. Long, R. Dummer, A. Ribas, I. Puzanov, O. Michielin, A. Vanderwalde, R.H.I. Andtbacka, J. Cebon, E. Fernandez, J. Malvehy, A.J. Olszanski, T.F. Gajewski, J.M. Kirkwood, C. Gause, L. Chen, D.R. Kaufman, J. Chou, F.S. Hodi

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2508955175

FWCI: 1.695

Cites:

Cited by: 16

Related to: 10